Actos Bladder Cancer Lawsuit Claims
Helping people who have suffered Actos and bladder cancer side effects after taking medications containing the drug pioglitazone and representing individuals diagnosed with cancer in filing an Actos bladder cancer lawsuit.
It has increasingly been reported that the drug pioglitazone (also referred to by the brand name Actos) which is prescribed to treat diabetes has been linked to an increased risk of developing bladder cancer in patients taking the medicine for longer than one year.
In June 2011 the Food and Drug Administration (FDA) announced that patients using the diabetes medicine Actos (generic name – pioglitazone) for longer than a year may be linked with an elevated risk for developing bladder cancer. There is currently no Actos recall.
Actos is the brand name of the drug pioglitazone and is manufactured by Takeda. It is prescribed to treat adults diagnosed with type 2 diabetes mellitus. For the first ten months in 2010, it is estimated 2.3 million people filled a prescription from a retail pharmacy for medication containing pioglitazone.
The FDA looked at data from a five year analysis that was based on an ongoing epidemiological study. This data formed the basis of the FDA’s safety information reported to the public regarding the link between Actos and bladder cancer. The FDA found that the longer patients took drugs containing pioglitazone, like Actos, the greater the risk of Actos causing bladder cancer. The same Actos and bladder cancer connection was also found in patients with the highest cumulative dose of the drug.
FDA recommendations for healthcare professionals include not using pioglitazone (Actos) in treating patients that have been diagnosed with bladder cancer that is active and using the drug with patients who have had bladder cancer in the past only after weighing the benefits of the medication against the chance that the cancer will reoccur.
Actos is available in several medication forms including:
• Actos (pioglitazone)
• Actoplus Met (pioglitazone/metformin)
• Actoplus Met XR (pioglitazone/metformin extended-release)
• Duetact (pioglitazone/glimepiride)
In June, 2011 the FDA approved Actos drug labeling changes that involved updated safety information regarding the higher Actos cancer risk for patients using the drug for longer than one year. In addition, the updated warning label included information warning that patients who have a history of bladder cancer or currently have bladder cancer should not be prescribed Actos.
Actos And Bladder Cancer Lawsuit Help
We represent all Actos lawsuit bladder cancer clients on a contingency basis which means that there are never any legal fees unless we win compensation in your case. For a free no-obligation consultation please call toll free or fill out our short online contact form and an Actos and bladder cancer lawsuit lawyer will contact you to answer any of your questions including any future Actos recall news.
Featured Actos Bladder Cancer Lawsuit News
Takeda Pharmaceuticals, maker of the type II diabetes medication Actos, submitted data from an ongoing 10-year study examining the Actos and cancer risk link to the...
The FDA announced in June 2011 that using the medication for longer than one year may contribute to Actos causing bladder cancer.Takeda Pharmaceuticals, maker of the...
Actos was introduced to the U.S. market in 1999, and is prescribed to treat diabetes mellitus type 2. Recently there have been concerns regarding the link between Actos...
If you have diabetes and have been using the prescription medicine Actos, you may be concerned about recent studies linking Actos causing bladder cancer.
On June 15, 2011, the Food and Drug Administration updated their Actos bladder cancer FDA safety information on the type 2 diabetes medication Actos (brand...
Making a Difference
We believe that the manufacturer of Actos should be held accountable for any harm they are legally responsible for and patients should be fairly compensated for their damages due to a diagnosis of cancer… find out more
Requesting a free legal consultation does not create an attorney-client relationship and you are not considered a client until a representation agreement has been signed and your case has been accepted.
Actos Bladder Cancer FDA
In June, 2011 the FDA approved Actos drug labeling changes that involved updated safety information regarding the higher Actos cancer risk for developing bladder cancer for patients using the drug for longer than one year. In addition, the updated warning label included information warning… find out more